AsiaNet 98626

BARCELONA, Spain, Nov. 4, 2022 /PRNewswire=KYODO JBN/ --

    -- Werfen enters into an agreement to acquire Immucor, Inc., a privately

       held, US-based corporation, with a solid global presence in transfusion

       and transplant in vitro diagnostics

    -- The transaction is expected to close during the first half of 2023

Werfen announced today that it has agreed to acquire Immucor, Inc., from TPG.

Immucor is a privately held corporation with a strong global presence in

transfusion and transplant in vitro diagnostics, headquartered in Norcross,

Georgia, USA. This acquisition will allow Werfen to expand its portfolio of

Specialized Diagnostics solutions for hospitals and clinical laboratories.

Photo -

https://mma.prnewswire.com/media/1937701/Werfen_President_Marc_Rubiralta.jpg

Logo - https://mma.prnewswire.com/media/1561045/Werfen_Logo.jpg

The purchase price is expected to be approximately US$2 billion, with closing

subject to customary regulatory approvals. The acquisition is being funded with

a mix of cash on hand and new senior credit facilities. The company does not

expect the transaction to impact its investment grade rating from Standard &

Poor's.

"As a global leader in the research, development, manufacturing and

distribution of innovative, Specialized Diagnostics solutions for hospitals and

clinical laboratories, Immucor is a natural fit with our existing business

model," said Marc Rubiralta, President of Werfen. "We highly value Immucor's

commitment to enhancing care for all patients in need of a transfusion or

transplant. This fits squarely with our long-term vision and strategy, aligns

with our focus, and complements Werfen's values."

Rubiralta added, "I am confident that by combining two complementary,

outstanding Specialized Diagnostics companies, Werfen will expand its global

presence with greater diversification, while successfully maintaining its focus

on specialization."

"Immucor's expertise and innovations in transfusion and transplant diagnostics

enable us to enter new markets and will help achieve our vision to be the

preferred choice of the most advanced laboratory and point-of-care customers,

globally," said Carlos Pascual, CEO of Werfen. "It will be a major milestone in

the future of Werfen."

Avi Pelossof, CEO of Immucor said, "As we look to the future, we are excited to

grow our impact as part of Werfen, a company that shares our long-term vision

and commitment to advancing patient care globally. As the value of diagnostics

in the healthcare system grows, we are confident that Immucor will continue to

innovate and succeed under Werfen's ownership."

Upon completion of this acquisition, and based on 2021 figures, Werfen will

surpass EUR2.2 billion in revenue, with seven technology centers, close to

7,000 employees worldwide, and a direct presence in 30 countries and more than

100 territories through distributors.

Werfen was advised by Barclays and Milbank LLP. BBVA, BNP Paribas, CaixaBank

and HSBC Holding plc provided commitments for the new senior credit facilities.

The sellers and Immucor were advised by Evercore and Ropes & Gray LLP.

Werfen

Founded  in 1966, Werfen is a worldwide developer, manufacturer and distributor

of Specialized Diagnostic instruments, related reagents, automation workcells,

and data management solutions for use primarily in hospitals and independent

clinical laboratories. The Company's business units include Hemostasis, Acute

Care Diagnostics, Autoimmunity, and Original Equipment Manufacturing (OEM).

Werfen operates directly in nearly 30 countries and in more than 100

territories through distributors. For more information, visit werfen.com [

https://c212.net/c/link/?t=0&l=en&o=3698708-1&h=2789340518&u=http%3A%2F%2Fwww.werfen.com%2F&a=werfen.com

]    

TPG

TPG is a leading global alternative asset management firm, founded in San

Francisco in 1992, with $127 billion of assets under management and investment

and operational teams in 12 offices globally. TPG invests across five

multi-product platforms: Capital, Growth, Impact, Real Estate, and Market

Solutions and our unique strategy is driven by collaboration, innovation, and

inclusion. Our teams combine deep product and sector experience with broad

capabilities and expertise to develop differentiated insights and add value for

our fund investors, portfolio companies, management teams, and communities. For

more information visit www.tpg.com or @TPG on Twitter.

Legal notice

This document contains forward-looking statements about our business, financial

data, and events related to the prospects of Werfen. These forecasts can be

identified by the use of words such as "expectation", "vision", "anticipation",

"intention", "plan", "belief", "search", "estimate", "future", "project", or

words with a similar meaning. We may also make projections in other reports,

presentations, and press releases. Furthermore, our sales representatives may

occasionally make forward-looking statements. These projections are based on

our current expectations and on certain hypotheses, many of which are beyond

the corporation's control and subject to a series of risks and uncertainties.

In the event that any of these risks or uncertainties should materialize or the

underlying expectations are not fulfilled, the results or performance of Werfen

may differ substantially (either positively or negatively) from those

explicitly or implicitly forecast. Werfen assumes no obligation to update or

revise any forward-looking statements made previously.

SOURCE Werfen

CONTACT: Werfen, Javier Gómez Aguado, CFO, Tel. +34 93 401 01 08,

jgomez@werfen.com